To test NG2 expression in preclinical DIPG murine models, we used IHC to assess NG2 expression in the PDGFB-Ink4a-ARF−/− mouse (PDGFB model) [16] as well as mouse injected with glioma cells derived from PDGFB/p53−/−/H3.3K27M model [17]. The gene discussed is CDKN2A; the disease is central nervous system cancer.